Youji Tsuchie, Presenter: Nothing to Disclose

Akihiko Wada MD, Abstract Co-Author: Nothing to Disclose

Ai Kobayashi, Abstract Co-Author: Nothing to Disclose

Takeshi Yoshizako MD, Abstract Co-Author: Nothing to Disclose

Kazuaki Yoshikawa, Abstract Co-Author: Nothing to Disclose

Kazushige Oda, Abstract Co-Author: Nothing to Disclose

Takashi Katsube, Abstract Co-Author: Nothing to Disclose

Nobue Uchida MD, Abstract Co-Author: Nothing to Disclose

Hajime Kitagaki, Abstract Co-Author: Nothing to Disclose

et al, Abstract Co-Author: Nothing to Disclose

et al, Abstract Co-Author: Nothing to Disclose

We evaluate US elastography findings of benign and malignant breast tumors and exhibit the boon that introduction of US elastography provides for breast cancer screening.

Subjects of this study were 2529 females who had breast cancer screening in our institution from October, 2005 to March, 2007. All subjects received both palpation and mammography, and ultrasonography was added to subjects having breast mass lesion. Conventional US and US elastography was performed with digital US scanner (EUB-8500; Hitachi Medical, Tokyo, Japan) and 7.5MHz liner electric probe (EUP-L54M; Hitachi Medical) with a stabilizer was adapted to obtain the adequate elasticity images.

B-mode US to 212 breast tumors revealed necessity of biopsy in 42 (19.8%) subjects and malignant lesion was confirmed pathologically in 13 (6%) subjects. In US elastography findings of 13 malignant tumors, the intratumoral elastic decay area occupied more than 50% of all tumors area in all cases. However, in 38% (11/29) of benign tumors, the intratumoral elastic decay area was less than 50% of all tumor area. When this US elastography criteria is introduced into our breast cancer screening, 38% of the subjects with benign breast tumor may be relieved from unnecessarily invasive biopsy.

US elastography becomes a new index of breast tumor diagnosis and provides a boon for the handling of the benign breast tumor patient in breast cancer screening.

US elastography becomes a new index of breast tumor diagnosis and introduction of US elastography to breast cancer screening provides a boon for benign breast tumor patients.

Tsuchie, Y, Wada, A, Kobayashi, A, Yoshizako, T, Yoshikawa, K, Oda, K, Katsube, T, Uchida, N, Kitagaki, H, et al, , et al, , Assessment of Breast Tumor with US Elastography: A New Decision Index in Breast Cancer Screening.  Radiological Society of North America 2007 Scientific Assembly and Annual Meeting, November 25 - November 30, 2007 ,Chicago IL. http://archive.rsna.org/2007/5003237.html